An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Orbcel-C (Primary)
- Indications Autoimmune hepatitis; Primary sclerosing cholangitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms MERLIN
- 11 Jul 2024 Planned End Date changed from 1 Dec 2023 to 1 Oct 2025.
- 11 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2022 Planned number of patients changed from 56 to 18.